东北和新泻地区老年患者原发性中枢神经系统淋巴瘤预后不良的临床病理危险因素:东北脑肿瘤研究组的多中心、回顾性、队列研究

IF 3 3区 医学 Q2 CLINICAL NEUROLOGY
Brain Tumor Pathology Pub Date : 2022-07-01 Epub Date: 2022-03-21 DOI:10.1007/s10014-022-00427-4
Kenichiro Asano, Yoji Yamashita, Takahiro Ono, Manabu Natsumeda, Takaaki Beppu, Kenichiro Matsuda, Masahiro Ichikawa, Masayuki Kanamori, Masashi Matsuzaka, Akira Kurose, Toshio Fumoto, Kiyoshi Saito, Yukihiko Sonoda, Kuniaki Ogasawara, Yukihiko Fujii, Hiroaki Shimizu, Hiroki Ohkuma, Chifumi Kitanaka, Takamasa Kayama, Teiji Tominaga
{"title":"东北和新泻地区老年患者原发性中枢神经系统淋巴瘤预后不良的临床病理危险因素:东北脑肿瘤研究组的多中心、回顾性、队列研究","authors":"Kenichiro Asano,&nbsp;Yoji Yamashita,&nbsp;Takahiro Ono,&nbsp;Manabu Natsumeda,&nbsp;Takaaki Beppu,&nbsp;Kenichiro Matsuda,&nbsp;Masahiro Ichikawa,&nbsp;Masayuki Kanamori,&nbsp;Masashi Matsuzaka,&nbsp;Akira Kurose,&nbsp;Toshio Fumoto,&nbsp;Kiyoshi Saito,&nbsp;Yukihiko Sonoda,&nbsp;Kuniaki Ogasawara,&nbsp;Yukihiko Fujii,&nbsp;Hiroaki Shimizu,&nbsp;Hiroki Ohkuma,&nbsp;Chifumi Kitanaka,&nbsp;Takamasa Kayama,&nbsp;Teiji Tominaga","doi":"10.1007/s10014-022-00427-4","DOIUrl":null,"url":null,"abstract":"<p><p>Clinicopathological risk factors for a poor prognosis were investigated in elderly patients with malignant lymphoma of the central nervous system. A total of 82 pathologically confirmed, CD20-positive, diffuse large B-cell lymphoma patients aged 71 years or older who underwent therapeutic intervention in the Tohoku and Niigata area in Japan were retrospectively reviewed. A univariate analysis was performed by the log-rank test using the Kaplan-Meier method. A Cox proportional hazards model was used for multivariate analysis of risk factors. Of the 82 patients, 39 were male and 43 were female, and their median age at onset was 75 years. At the end of the study, there were 34 relapse-free patients (41.5%), 48 relapse cases (58.5%), median progression-free survival was 18 months, and median overall survival (OS) was 26 months; there were 41 deaths and 41 survivors. Multivariate analysis of median OS showed that Karnofsky Performance Status less than 60% 3 months after treatment (p = 0.022, hazard ratio (HR) = 2.591) was the clinical risk factor, and double expressor lymphoma (p = 0.004, HR = 3.163), expression of programmed death-ligand 1 in tumor infiltrating lymphocytes or tumor-associated macrophages (p < 0.001, HR = 5.455), and Epstein-Barr virus infection (p = 0.031, HR = 5.304) were the pathological risk factors.</p>","PeriodicalId":9226,"journal":{"name":"Brain Tumor Pathology","volume":" ","pages":"139-150"},"PeriodicalIF":3.0000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group.\",\"authors\":\"Kenichiro Asano,&nbsp;Yoji Yamashita,&nbsp;Takahiro Ono,&nbsp;Manabu Natsumeda,&nbsp;Takaaki Beppu,&nbsp;Kenichiro Matsuda,&nbsp;Masahiro Ichikawa,&nbsp;Masayuki Kanamori,&nbsp;Masashi Matsuzaka,&nbsp;Akira Kurose,&nbsp;Toshio Fumoto,&nbsp;Kiyoshi Saito,&nbsp;Yukihiko Sonoda,&nbsp;Kuniaki Ogasawara,&nbsp;Yukihiko Fujii,&nbsp;Hiroaki Shimizu,&nbsp;Hiroki Ohkuma,&nbsp;Chifumi Kitanaka,&nbsp;Takamasa Kayama,&nbsp;Teiji Tominaga\",\"doi\":\"10.1007/s10014-022-00427-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Clinicopathological risk factors for a poor prognosis were investigated in elderly patients with malignant lymphoma of the central nervous system. A total of 82 pathologically confirmed, CD20-positive, diffuse large B-cell lymphoma patients aged 71 years or older who underwent therapeutic intervention in the Tohoku and Niigata area in Japan were retrospectively reviewed. A univariate analysis was performed by the log-rank test using the Kaplan-Meier method. A Cox proportional hazards model was used for multivariate analysis of risk factors. Of the 82 patients, 39 were male and 43 were female, and their median age at onset was 75 years. At the end of the study, there were 34 relapse-free patients (41.5%), 48 relapse cases (58.5%), median progression-free survival was 18 months, and median overall survival (OS) was 26 months; there were 41 deaths and 41 survivors. Multivariate analysis of median OS showed that Karnofsky Performance Status less than 60% 3 months after treatment (p = 0.022, hazard ratio (HR) = 2.591) was the clinical risk factor, and double expressor lymphoma (p = 0.004, HR = 3.163), expression of programmed death-ligand 1 in tumor infiltrating lymphocytes or tumor-associated macrophages (p < 0.001, HR = 5.455), and Epstein-Barr virus infection (p = 0.031, HR = 5.304) were the pathological risk factors.</p>\",\"PeriodicalId\":9226,\"journal\":{\"name\":\"Brain Tumor Pathology\",\"volume\":\" \",\"pages\":\"139-150\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brain Tumor Pathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10014-022-00427-4\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/3/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain Tumor Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10014-022-00427-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/3/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 3

摘要

探讨老年中枢神经系统恶性淋巴瘤患者预后不良的临床病理危险因素。回顾性分析了82例病理证实的cd20阳性弥漫性大b细胞淋巴瘤患者,年龄71岁或以上,在日本东北和新泻地区接受了治疗干预。单因素分析采用Kaplan-Meier法进行log-rank检验。采用Cox比例风险模型对危险因素进行多因素分析。82例患者中,男性39例,女性43例,发病年龄中位数为75岁。研究结束时,无复发患者34例(41.5%),复发病例48例(58.5%),中位无进展生存期为18个月,中位总生存期(OS)为26个月;41人死亡,41人幸存。中位OS的多因素分析显示,治疗后3个月Karnofsky Performance Status低于60% (p = 0.022,危险比(HR) = 2.591)是临床危险因素,双表达型淋巴瘤(p = 0.004,危险比(HR) = 3.163)、肿瘤浸润淋巴细胞或肿瘤相关巨噬细胞中程序性死亡配体1的表达(p = 0.004,风险比)为临床危险因素
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group.

Clinicopathological risk factors for a poor prognosis were investigated in elderly patients with malignant lymphoma of the central nervous system. A total of 82 pathologically confirmed, CD20-positive, diffuse large B-cell lymphoma patients aged 71 years or older who underwent therapeutic intervention in the Tohoku and Niigata area in Japan were retrospectively reviewed. A univariate analysis was performed by the log-rank test using the Kaplan-Meier method. A Cox proportional hazards model was used for multivariate analysis of risk factors. Of the 82 patients, 39 were male and 43 were female, and their median age at onset was 75 years. At the end of the study, there were 34 relapse-free patients (41.5%), 48 relapse cases (58.5%), median progression-free survival was 18 months, and median overall survival (OS) was 26 months; there were 41 deaths and 41 survivors. Multivariate analysis of median OS showed that Karnofsky Performance Status less than 60% 3 months after treatment (p = 0.022, hazard ratio (HR) = 2.591) was the clinical risk factor, and double expressor lymphoma (p = 0.004, HR = 3.163), expression of programmed death-ligand 1 in tumor infiltrating lymphocytes or tumor-associated macrophages (p < 0.001, HR = 5.455), and Epstein-Barr virus infection (p = 0.031, HR = 5.304) were the pathological risk factors.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Brain Tumor Pathology
Brain Tumor Pathology 医学-病理学
CiteScore
5.40
自引率
9.10%
发文量
30
审稿时长
>12 weeks
期刊介绍: Brain Tumor Pathology is the official journal of the Japan Society of Brain Tumor Pathology. This international journal documents the latest research and topical debate in all clinical and experimental fields relating to brain tumors, especially brain tumor pathology. The journal has been published since 1983 and has been recognized worldwide as a unique journal of high quality. The journal welcomes the submission of manuscripts from any country. Membership in the society is not a prerequisite for submission. The journal publishes original articles, case reports, rapid short communications, instructional lectures, review articles, letters to the editor, and topics.Review articles and Topics may be recommended at the annual meeting of the Japan Society of Brain Tumor Pathology. All contributions should be aimed at promoting international scientific collaboration.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信